TR201902864T4 - Beta-klorosiklopentanların hidrofilik ester ön ilaçlarının kullanımı ile azaltılmış merkezi korneal kalınlaşma. - Google Patents

Beta-klorosiklopentanların hidrofilik ester ön ilaçlarının kullanımı ile azaltılmış merkezi korneal kalınlaşma. Download PDF

Info

Publication number
TR201902864T4
TR201902864T4 TR2019/02864T TR201902864T TR201902864T4 TR 201902864 T4 TR201902864 T4 TR 201902864T4 TR 2019/02864 T TR2019/02864 T TR 2019/02864T TR 201902864 T TR201902864 T TR 201902864T TR 201902864 T4 TR201902864 T4 TR 201902864T4
Authority
TR
Turkey
Prior art keywords
chlorocyclopentanes
beta
ester prodrugs
central corneal
hydrophilic ester
Prior art date
Application number
TR2019/02864T
Other languages
English (en)
Inventor
M Burk Robert
Bin Im Wha
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/185,556 external-priority patent/US9090595B2/en
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of TR201902864T4 publication Critical patent/TR201902864T4/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Glokomun tedavisine yönelik bileşimler ve yöntemler sağlanmaktadır. Özellikle aşağıda bahsedilen formülün hidrofilik ester ön ilaçları ve bunların merkezi korneal kalınlaşmayı azaltmak üzere kullanımı sağlanmaktadır. (I)
TR2019/02864T 2014-02-20 2015-02-19 Beta-klorosiklopentanların hidrofilik ester ön ilaçlarının kullanımı ile azaltılmış merkezi korneal kalınlaşma. TR201902864T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US14/185,556 US9090595B2 (en) 2012-08-27 2014-02-20 Reduced central corneal thickening by use of hydrophilic ester prodrugs of beta-chlorocyclopentanes

Publications (1)

Publication Number Publication Date
TR201902864T4 true TR201902864T4 (tr) 2019-03-21

Family

ID=54062793

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2019/02864T TR201902864T4 (tr) 2014-02-20 2015-02-19 Beta-klorosiklopentanların hidrofilik ester ön ilaçlarının kullanımı ile azaltılmış merkezi korneal kalınlaşma.

Country Status (10)

Country Link
EP (1) EP3107906B1 (tr)
JP (1) JP6626831B2 (tr)
KR (1) KR20160124835A (tr)
CN (1) CN106029643A (tr)
AU (1) AU2015259752B2 (tr)
CA (1) CA2939569A1 (tr)
DK (1) DK3107906T3 (tr)
ES (1) ES2717481T3 (tr)
TR (1) TR201902864T4 (tr)
WO (1) WO2015175075A1 (tr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015327817B2 (en) 2014-10-02 2020-04-23 Allergan, Inc. Ester prodrugs of gamma-lactams and their use
JP7197880B2 (ja) * 2017-10-19 2022-12-28 学校法人 名城大学 エステル化剤及びその利用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
JP2594486B2 (ja) 1991-01-15 1997-03-26 アルコン ラボラトリーズ インコーポレイテッド 局所的眼薬組成物
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
WO2008008718A2 (en) * 2006-07-11 2008-01-17 Allergan, Inc. Cyclopentane derivatives as antiglaucoma agents
US20080015219A1 (en) * 2006-07-11 2008-01-17 Allergan, Inc. Therapeutic compounds
US7947732B2 (en) * 2007-07-13 2011-05-24 Allergan, Inc. Therapeutic substituted chlorocyclopentanols
US7960378B2 (en) * 2008-03-18 2011-06-14 Allergan, Inc. Therapeutic compounds
US7732443B2 (en) * 2008-03-18 2010-06-08 Yariv Donde Therapeutic substituted cyclopentanes
US7737140B2 (en) * 2008-04-24 2010-06-15 Allergan, Inc. Therapeutic compounds
KR101769637B1 (ko) 2009-11-09 2017-08-18 알러간, 인코포레이티드 모발 성장을 촉진하기 위한 조성물 및 방법
US20110136872A1 (en) * 2009-12-09 2011-06-09 Burk Robert M Stable aqueous compositions of prostglandin agonist prodrugs and methods for use thereof
TR201900863T4 (tr) * 2012-08-27 2019-02-21 Allergan Inc Beta-klorosiklopentanların hidrofilik ester ön ilaçlarının kullanılmasıyla merkezi korneal kalınlaşmanın azaltılması.

Also Published As

Publication number Publication date
CA2939569A1 (en) 2015-11-19
AU2015259752B2 (en) 2019-06-20
JP2017509610A (ja) 2017-04-06
AU2015259752A1 (en) 2016-09-01
CN106029643A (zh) 2016-10-12
DK3107906T3 (en) 2019-03-18
KR20160124835A (ko) 2016-10-28
EP3107906B1 (en) 2018-12-05
JP6626831B2 (ja) 2019-12-25
WO2015175075A1 (en) 2015-11-19
EP3107906A1 (en) 2016-12-28
ES2717481T3 (es) 2019-06-21

Similar Documents

Publication Publication Date Title
MX2017006302A (es) Derivados de adenina que son utiles en el tratamiento de enfermedades alergicas u otras afecciones inflamatorias.
UY34750A (es) ?compuestos para el tratamiento del hiv, composiciones,métodos de preparación, intermediarios y métodos terapéuticos?.
MX2017008444A (es) Picolinamidas como fungicidas.
NZ728072A (en) Modulators of toll-like receptors for the treatment of hiv
EA201691582A1 (ru) Новые фармацевтические препараты
EA201790273A1 (ru) Флагеллиновые композиции и их применение
TR201901886T4 (tr) DNA-PK inhibitörleri.
MA40076A (fr) Inhibiteurs de syk
UY34201A (es) Compuestos de azaindol y métodos para el tratamiento de vih.
TR201900863T4 (tr) Beta-klorosiklopentanların hidrofilik ester ön ilaçlarının kullanılmasıyla merkezi korneal kalınlaşmanın azaltılması.
UY34472A (es) Derivados modificados de 4-fenil-piridina
PH12017500481A1 (en) Novel soluble guanylate cyclase activators and their use
CL2016002091A1 (es) Compuesto de triazina y su uso para fines medicinales
EA201591406A1 (ru) C-19 модифицированные тритерпеноиды с ингибиторной активностью созревания вич
FR3024465B1 (fr) Caracterisation de micro-organismes par maldi-tof
UY36500A (es) Composiciones del inhibidor de la nitrificación y métodos de preparación de las mismas
UY36070A (es) Triterpenoides con actividad inhibidora de la maduración de hiv
DOP2016000278A (es) Nuevos compuestos macrocíclicos
UY36868A (es) Composiciones para tratamiento de enfermedades mediadas por interleuquina 5 (il-5)
UY35274A (es) Compuestos y métodos para tratar infecciones bacterianas
MD20170011A2 (ro) Compuşi imidazopiridazinici
MX2017005578A (es) Métodos de administración de composiciones de amantadina.
MX2017003550A (es) Uso de cisteamina en tratamiento de infecciones causadas por levaduras/mohos.
ZA201703467B (en) Methods of treating ocular conditions
BR112016027455A2 (pt) moduladores ppar